ISR - IsoRay, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.4200
-0.0009 (-0.21%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.4209
Open0.4120
Bid0.00 x 1100
Ask0.58 x 900
Day's Range0.4100 - 0.4300
52 Week Range0.3600 - 1.2200
Volume70,568
Avg. Volume307,696
Market Cap28.279M
Beta (3Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateFeb 7, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.20
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    IsoRay Names Jonathan Hunt New Chief Financial Officer

    Hunt has more than 25 years of finance and accounting experience excelling as a versatile leader with a successful track record in turnarounds, startups, mergers, divestitures, growth strategies, performance and operations management and analysis at a number of organizations, including Fortune 500 companies. “We are excited to have Jonathan back at IsoRay. Before joining IsoRay, Hunt was Chief Financial Officer at Vivid Learning Systems, where he had a central role in the company’s turnaround, that included growing revenues and implementing financial policy and process changes that ultimately resulted in the successful sale of the company.

  • GlobeNewswire20 days ago

    Report: Exploring Fundamental Drivers Behind Micron Solutions, Gentherm, ENSERVCO, IsoRay, Trilogy Metals, and Xtant Medical — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates
    Zackslast month

    IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates

    IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -9.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    IsoRay: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the Richland, Washington-based company said it had a loss of 2 cents. The isotope-based medical products maker posted revenue of $1.6 million in the period. In the final minutes of ...

  • GlobeNewswire2 months ago

    IsoRay To Announce First Quarter Fiscal 2019 Financial Results on November 8, 2018

    IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2019 ended September 30, 2018 on Thursday, November 8, 2018, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal 2019 after the close of the U.S. stock markets on November 8, 2018.

  • Associated Press3 months ago

    IsoRay: Fiscal 4Q Earnings Snapshot

    On a per-share basis, the Richland, Washington-based company said it had a loss of 4 cents. The isotope-based medical products maker posted revenue of $1.6 million in the period. For the year, the company ...

  • GlobeNewswire3 months ago

    IsoRay Announces Fourth Quarter and Full-Year 2018 Financial Results

    Year over year fourth quarter revenues increased 17%Sixth Consecutive Quarter of Year-Over-Year Revenue IncreasesFull year revenues increased 24% RICHLAND, Wash., Sept. 25,.

  • When Can We Expect A Profit From IsoRay Inc (NYSEMKT:ISR)?
    Simply Wall St.3 months ago

    When Can We Expect A Profit From IsoRay Inc (NYSEMKT:ISR)?

    IsoRay Inc’s (NYSEMKT:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases inRead More...

  • What You Must Know About IsoRay Inc’s (NYSEMKT:ISR) Financial Strength
    Simply Wall St.3 months ago

    What You Must Know About IsoRay Inc’s (NYSEMKT:ISR) Financial Strength

    The direct benefit for IsoRay Inc (NYSEMKT:ISR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off isRead More...

  • ACCESSWIRE5 months ago

    Free Technical Research on IsoRay and Three More Medical Supplies Equities

    On Friday, July 20, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: IsoRay Inc. (NYSE AMER: ISR), STAAR Surgical Co. (NASDAQ: STAA), Conformis Inc. (NASDAQ: CFMS), and Integra LifeSciences Holdings Corp. (NASDAQ: IART).

  • ACCESSWIRE5 months ago

    Today's Research Reports on Stocks to Watch: Staffing 360 Solutions and IsoRay

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Both Staffing 360 Solutions and IsoRay were two of the biggest winners in Monday’s trading session with gains of about 300% and 143% respectively. The company, which is an innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, said it plans to use the net proceeds from this offering for working capital and general corporate purposes with particular focus on marketing the brain applications and Build-Blu™ delivery system for real-time prostate brachytherapy.

  • IsoRay Stock Jumps 160% on FDA Clearance for Brain Tumor Therapy
    Market Realist5 months ago

    IsoRay Stock Jumps 160% on FDA Clearance for Brain Tumor Therapy

    Today, IsoRay Inc. (ISR) stock rallied ~160% and closed trading at $1.14, compared to its previous closing price of $0.44. IsoRay’s stock price was triggered by buoyed investor sentiment on the news of the FDA 510(k) clearance for the company’s GammaTile therapy for the treatment of recurrent brain tumors.

  • ACCESSWIRE7 months ago

    IsoRay to Present at the 8th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment ...

  • When Will IsoRay Inc (NYSEMKT:ISR) Breakeven?
    Simply Wall St.7 months ago

    When Will IsoRay Inc (NYSEMKT:ISR) Breakeven?

    IsoRay Inc’s (AMEX:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases inRead More...

  • ACCESSWIRE7 months ago

    IsoRay, Inc. Discusses Competitive Landscape, FDA Clearance for New Product Line and Growth Drivers in New SNNLive Video Interview with StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / May 17, 2018 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Tom LaVoy, Chairman of the Board & CEO of IsoRay, Inc. ...

  • Want To Invest In IsoRay Inc (NYSEMKT:ISR)? Here’s How It Performed Lately
    Simply Wall St.7 months ago

    Want To Invest In IsoRay Inc (NYSEMKT:ISR)? Here’s How It Performed Lately

    For long term investors, improvement in profitability and outperformance against the industry can be important characteristics in a stock. In this article, I will take a look at IsoRay Inc’sRead More...